liposomes only a small.proportion of the drug may become encapsulated, and subsequent retention is highly dependent on the integrity of the liposomal membranes (Stamp & Juliano, 1979) . One solution to this problem is to modify the compound by the addition of lipophilic side-chains, so that it partitions into the lipid rather than into the aqueous phase (Knight, 1981) . We have synthesized some N-acyl derivatives of daunorubicin and measured their retention within dimyristoylphosphatidylcholine (DMPC) liposomes. We report below the toxicity of these liposomes to L929 cells in culture.
Daunorubicin-HCl was kindly given by Farmitalia, Milan, Italy. N-Acyl daunorubicin derivatives with acyl chain lengths of 2, 4, 8 and 16 carbon atoms were made by the mixed-anhydride method (Albertson, 1962) (Figure) obtained by diluting a liposome suspension initially containing 800 ,uM DMPC, 95 ,uM Nacyl daunorubicin and 45 ,uM DPPA, revealed that DRO was more cytotoxic than DRP in the concentration range 5 to 95utM (P < 0-01) though both derivatives were less active than free daunorubicin (P < 0 01). However, when the DMPC concentration was kept constant at 800 ,uM and the dose of DRO was decreased by lowering the proportion of the drug in the liposomes, there was a marked enhancement of cytotoxicity at the lower con- centration (Figure) . Indeed, DMPC liposomes (800 ,uM) containing 0'8 ,uM DRO were more cytotoxic than free daunorubicin at the same concentration. Microscopic examination of L929 cells incubated with DRO liposomes showed an intense orange fluorescence that appeared initially to be located principally in the cytoplasm, but spread to the nucleus as the incubation proceeded. Cells incubated with DRP liposomes showed a similar staining pattern, though nuclear fluorescence appeared rather later. Cells incubated with daunorubicin or daunorubicin-DNA showed strong nuclear fluorescence after 2 h, and little or no cytoplasmic fluorescence at any stage.
We have found that 10 mol% of Nacyl daunorubicin can be incorporated efficiently into DMPC liposomes, provided that the N-acyl substituent is 8 or more carbon atoms long. Both DRO and DRP remained associated with the liposomes during incubation for 5 days in culture medium containing 10% newborn calf-serum.
Dose-response curves (Figure) showed that liposomes containing 10 mol % Nacyl daunorubicins were less cytotoxic to L929 cells than free daunorubicin. This difference appeared to be due to Nsubstitution, as found by Aszalos et al. (1979) with another cell line, since the toxicity of the analogues was related to the lengths of the N-acyl chain, and could not be accounted for by differences in incorporation or retention by liposomes. Furthermore, the toxicity of liposomal N-acyl daunorubicins to L929 cells was highly dependent on lipid concentration, confirming that their action was mediated by the liposomes, though the mechanisms involved were not investigated. The mode of action of N-acyl daunorubicins is not entirely clear, and may differ from that of the unmodified compound (Aszalos et al., 1979) . Free daunorubicin can interact with the DNA double helix and block transcription (Ward et al., 1965) but N-acyl daunorubicins do not interact specifically with DNA (Aszalos et al., 1979; Di Marco & Arcamone, 1975) . Daunorubicin can also act by inhibiting respiration (Murphree et al., 1976) and by generating superoxide radicals (Bozzi et al., 1981) and these mechanisms of cytotoxicity would predominate in the case of analogues unable to bind to DNA. Our observations that N-acyl daunorubicins or their metabolites can eventually enter the nucleus, and that DRO, which accumulates in the nucleus more rapidly, is the more toxic, suggest that these compounds may be metabolized in L929 cells to derivatives which can bind to DNA and act in a, manner analogous to the parent compound.
